MacroGenics (MGNX) Insider Trading & Ownership $1.29 +0.04 (+3.20%) Closing price 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.39%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MacroGenics (NASDAQ:MGNX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.30%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$12.18 MNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$1.66 M Get MGNX Insider Trade Alerts Want to know when executives and insiders are buying or selling MacroGenics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MGNX Insider Buying and Selling by Quarter Remove Ads MacroGenics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/4/2024Jeffrey Stuart PetersVPSell51,395$15.55$799,192.25 2/26/2024Jeffrey Stuart PetersVPSell16,124$17.22$277,655.28 2/1/2024Ezio BonviniSVPSell13,316$15.00$199,740.00 1/19/2024Ezio BonviniSVPSell13,316$12.00$159,792.00 12/20/2023Ezio BonviniSVPSell18,880$10.08$190,310.40 10/2/2023Target N V BiotechMajor ShareholderBuy150,000$4.46$669,000.00 9/7/2023Target N V BiotechMajor ShareholderBuy200,000$5.26$1,052,000.00 8/30/2023Edward HurwitzDirectorBuy15,000$4.91$73,650.00 3/10/2023Jeffrey Stuart PetersVPSell5,372$6.03$32,393.16 2/14/2023Target N V BiotechMajor ShareholderBuy500,000$5.07$2,535,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 1/19/2023Target N V BiotechMajor ShareholderBuy150,000$5.30$795,000.00 12/27/2022Target N V BiotechMajor ShareholderBuy200,000$5.61$1,122,000.00 12/23/2022Target N V BiotechMajor ShareholderBuy200,000$5.88$1,176,000.00 11/22/2022Target N V BiotechMajor ShareholderBuy300,000$5.96$1,788,000.00 10/24/2022Target N V BiotechMajor ShareholderBuy250,000$4.36$1,090,000.00 10/21/2022Target N V BiotechMajor ShareholderBuy250,000$4.63$1,157,500.00 10/19/2022Target N V BiotechMajor ShareholderBuy168,422$3.70$623,161.40 6/15/2022James KarrelsCFOBuy40,000$2.47$98,800.00 (Data available from 1/1/2013 forward) MGNX Insider Trading Activity - Frequently Asked Questions Who is on MacroGenics's Insider Roster? The list of insiders at MacroGenics includes Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, and Target N V Biotech. Learn more on insiders at MGNX. What percentage of MacroGenics stock is owned by insiders? 11.30% of MacroGenics stock is owned by insiders. Learn more on MGNX's insider holdings. Which MacroGenics insiders have been buying company stock? The following insiders have purchased MGNX shares in the last 24 months: Edward Hurwitz ($73,650.00), and Target N V Biotech ($1,721,000.00). How much insider buying is happening at MacroGenics? Insiders have purchased a total of 365,000 MGNX shares in the last 24 months for a total of $1,794,650.00 bought. Which MacroGenics insiders have been selling company stock? The following insiders have sold MGNX shares in the last 24 months: Ezio Bonvini ($549,842.40), and Jeffrey Stuart Peters ($1,076,847.53). How much insider selling is happening at MacroGenics? Insiders have sold a total of 113,031 MacroGenics shares in the last 24 months for a total of $1,626,689.93 sold. MacroGenics Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Compensation: $1.2MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Compensation: $693.31kDr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Compensation: $766.85kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Compensation: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Compensation: $550.97kDr. Ezio Bonvini M.D. (Age 70)Senior VP of Research & Chief Scientific Officer Compensation: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Ms. Lynn Cilinski (Age 66)VP, Controller & Treasurer More Insider Trading Tools from MarketBeat Related Companies Allogene Therapeutics Insider Selling Amylyx Pharmaceuticals Insider Selling Benitec Biopharma Insider Selling Cryoport Insider Selling Astria Therapeutics Insider Selling Aura Biosciences Insider Selling Alumis Insider Selling Arcturus Therapeutics Insider Selling Aquestive Therapeutics Insider Selling Solid Biosciences Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Joby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April? This page (NASDAQ:MGNX) was last updated on 4/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.